STTK (Shattuck Labs) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STTK Shattuck Labs Inc STTK
42 GF Score
Price $7.42
GF Value $1.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shattuck Labs Net Loan?

Net Loan only applies to banks and insurance companies.

STTK
42GF Score
Shattuck Labs Inc STTK
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shattuck Labs (STTK) Overvalued in 2026?

Based on GuruFocus' analysis, Shattuck Labs stock appears to be overvalued. The current stock price of $7.42 is trading 606.7% above its estimated GF Value™ of $1.05. GuruFocus considers Shattuck Labs to be Significantly Overvalued.

Key valuation signals for STTK:

  • Net Loan:
  • GF Value™: $1.05 vs. price of $7.42 (606.7% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the STTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shattuck Labs Business Description

Address 500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
42GF Score

Get the complete analysis for STTK

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.42
Price
$1.05
GF Value